ReviewHuman vaccines & immunotherapeutics2014
Immune-based treatment and prevention of Clostridium difficile infection.
Review in Human vaccines & immunotherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Article
- Current and Ongoing Developments in TargetingMicroorganisms · 2024Review
- Oral Immunization with Nontoxigenic Clostridium difficile Strains Expressing Chimeric Fragments of TcdA and TcdB Elicits Protective Immunity against C. difficile Infection in Both Mice and Hamsters.Infection and immunity · 2018Article
- Healthcare-associated Clostridium difficile infection: role of correct hand hygiene in cross-infection control.Journal of preventive medicine and hygiene · 2018Article
- Review
- Article
- Bezlotoxumab.Hospital pharmacy · 2017Article
- Immunization with Recombinant TcdB-Encapsulated Nanocomplex Induces Protection againstFrontiers in microbiology · 2017Article
- Infection prevention and control ofJournal of global health · 2016Review
- Immunogenicity and protective efficacy of recombinant Clostridium difficile flagellar protein FliC.Emerging microbes & infections · 2016Article
- Gastrointestinal dysbiosis and the use of fecal microbial transplantation in Clostridium difficile infection.World journal of gastrointestinal pathophysiology · 2015Review
- Antibiotic therapy and Clostridium difficile infection - primum non nocere - first do no harm.Infection and drug resistance · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Clostridium difficile (C. difficile) causes over 500,000 infections per year in the US, with an estimated 15,000 deaths and an estimated cost of $1-3 billion. Moreover, a continual rise in the incidence of severe C. difficile infection (CDI) has been observed worldwide. Currently, standard treatment for CDI is the administration of antibiotics. While effective, these treatments do not prevent and may contribute to a disease recurrence rate of 15-35%. Prevention of recurrence is one of the most challenging aspects in the field. A better knowledge of the molecular mechanisms of the disease, the host immune response and identification of key virulence factors of C. difficilenow permits the development of immune-based therapies. Antibodies specific for C. difficile toxins have been shown to effectively treat CDI and prevent disease relapse in animal models and in humans. Vaccination has been recognized as the most cost-effective treatment/prevention for CDI. This review will summarize CDI transmission, epidemiology, major virulent factors and highlights the rational and the development of immune-based approaches against this remerging threat.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.